EUCAST expert rules in antimicrobial susceptibility testing

被引：495

作者：

Leclercq, R. ^{[1
,2
]}

Canton, R. ^{[2
,3
,4
,5
]}

Brown, D. F. J. ^{[5
]}

Giske, C. G. ^{[2
,5
,6
]}

Heisig, P. ^{[2
,7
]}

MacGowan, A. P. ^{[5
,8
]}

Mouton, J. W. ^{[5
,9
]}

Nordmann, P. ^{[2
,10
]}

Rodloff, A. C. ^{[5
,11
]}

Rossolini, G. M. ^{[2
,12
]}

Soussy, C. -J. ^{[5
,13
]}

Steinbakk, M. ^{[5
,14
]}

Winstanley, T. G. ^{[2
,15
]}

Kahlmeter, G. ^{[5
,16
]}

机构：

[1] CHU Cote Nacre, Lab Microbiol, Caen, France

[2] Hosp Univ Ramon y Cajal, IRYCIS, EUCAST Subcomm Expert Rules, Madrid, Spain

[3] Hosp Univ Ramon y Cajal, IRYCIS, Microbiol Serv, Madrid, Spain

[4] Hosp Univ Ramon y Cajal, IRYCIS, CIBERESP, Madrid, Spain

[5] Karolinska Univ Hosp, EUCAST Steering Comm, Solna, Sweden

[6] Karolinska Univ Hosp, MTC Karolinska Inst, Solna, Sweden

[7] Univ Hamburg, Dept Pharm Biol & Microbiol, Hamburg, Germany

[8] Southmead Hosp, Dept Med Microbiol, Bristol, Avon, England

[9] Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, NL-6525 ED Nijmegen, Netherlands

[10] Hop Bicetre, Serv Bacteriol Virol, Le Kremlin Bicetre, France

[11] Univ Leipzig, Inst Med Mikrobiol, D-04109 Leipzig, Germany

[12] Dipartimento Biotecnol, Sez Microbiol, Siena, Italy

[13] Hop Henri Mondor, Serv Bacteriol, F-94010 Creteil, France

[14] Norwegian Inst Publ Hlth, Div Infect Dis Control, Dept Bacteriol & Immunol, Oslo, Norway

[15] Royal Hallamshire Hosp, Dept Microbiol, Sheffield S10 2JF, S Yorkshire, England

[16] Cent Hosp Vaxjo, Vaxjo, Sweden

来源：

CLINICAL MICROBIOLOGY AND INFECTION | 2013年 / 19卷 / 02期

关键词：

Antimicrobial susceptibility testing; breakpoints; EUCAST; expert rules; interpretive reading; SPECTRUM-BETA-LACTAMASE; AMINOGLYCOSIDE-MODIFYING ENZYMES; RESISTANT STAPHYLOCOCCUS-AUREUS; MEDIATED GENTAMICIN RESISTANCE; AMINO-ACID SUBSTITUTIONS; ESCHERICHIA-COLI; STREPTOCOCCUS-PNEUMONIAE; HAEMOPHILUS-INFLUENZAE; KLEBSIELLA-PNEUMONIAE; QUINUPRISTIN-DALFOPRISTIN;

D O I：

10.1111/j.1469-0691.2011.03703.x

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

EUCAST expert rules have been developed to assist clinical microbiologists and describe actions to be taken in response to specific antimicrobial susceptibility test results. They include recommendations on reporting, such as inferring susceptibility to other agents from results with one, suppression of results that may be inappropriate, and editing of results from susceptible to intermediate or resistant or from intermediate to resistant on the basis of an inferred resistance mechanism. They are based on current clinical and/or microbiological evidence. EUCAST expert rules also include intrinsic resistance phenotypes and exceptional resistance phenotypes, which have not yet been reported or are very rare. The applicability of EUCAST expert rules depends on the MIC breakpoints used to define the rules. Setting appropriate clinical breakpoints, based on treating patients and not on the detection of resistance mechanisms, may lead to modification of some expert rules in the future.

引用

页码：141 / 160

页数：20

共 123 条

[1] Different aminoglycoside-resistant phenotypes in a rabbit Staphylococcus aureus endocarditis infection model [J].

Asseray, N ;

Caillon, J ;

Roux, N ;

Jacqueline, C ;

Bismuth, R ;

Kergueris, MF ;

Potel, G ;

Bugnon, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (05) :1591-1593

[2] Aminoglycoside-modifying enzymes: mechanisms of catalytic processes and inhibition [J].

Azucena, E ;

Mobashery, S .

DRUG RESISTANCE UPDATES, 2001, 4 (02) :106-117

[3] Combination of quinupristin-dalfopristin and gentamicin against methicillin-resistant Staphylococcus aureus:: Experimental rabbit endocarditis study [J].

Batard, E ;

Jacqueline, C ;

Boutoille, D ;

Hamel, A ;

Drugeon, HB ;

Asseray, N ;

Leclercq, R ;

Caillon, J ;

Potel, G ;

Bugnon, D .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (07) :2174-2178

[4]

BENVENISTE R, 1971, BIOCHEMISTRY-US, V10, P1787

[5] R-FACTOR MEDIATED GENTAMICIN RESISTANCE - NEW ENZYME WHICH MODIFIES AMINOGLYCODIDE ANTIBIOTICS [J].

BENVENISTE, R ;

DAVIES, J .

FEBS LETTERS, 1971, 14 (05) :293-+

[6] Outcomes evaluation of patients with ESBL- and non-ESBL-producing Escherichia coli and Klebsiella species as defined by CLSI reference methods:: report from the SENTRY Antimicrobial Surveillance Program [J].

Bhavnani, SM ;

Ambrose, PG ;

Craig, WA ;

Dudley, MN ;

Jones, RN .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2006, 54 (03) :231-236

[7] Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli [J].

Bin, Cao ;

Hui, Wang ;

Zhu Renyuan ;

Ning Yongzhong ;

Xie Xiuli ;

Xu Yingchun ;

Zhu Yuanjue ;

Chen Minjun .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2006, 56 (04) :351-357

[8] Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa [J].

Bonomo, Robert A. ;

Szabo, Dora .

CLINICAL INFECTIOUS DISEASES, 2006, 43 :S49-S56

[9] Combination of altered PBPs and expression of cloned extended-spectrum β-lactamases confers cefotaxime resistance in Haemophilus influenzae [J].

Bozdogan, B ;

Tristram, S ;

Appelbaum, PC .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (04) :747-749

[10] Detection of methicillin/oxacillin resistance in staphylococci [J].

Brown, DFJ .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2001, 48 :65-70

← 1 2 3 4 5 6 7 8 9 10 →